Literature DB >> 16254342

Laser-capture microdissection: refining estimates of the quantity and distribution of latent herpes simplex virus 1 and varicella-zoster virus DNA in human trigeminal Ganglia at the single-cell level.

Kening Wang1, Tsz Y Lau, Melissa Morales, Erik K Mont, Stephen E Straus.   

Abstract

There remains uncertainty and some controversy about the percentages and types of cells in human sensory nerve ganglia that harbor latent herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV) DNA. We developed and validated laser-capture microdissection and real-time PCR (LCM/PCR) assays for the presence and copy numbers of HSV-1 gG and VZV gene 62 sequences in single cells recovered from sections of human trigeminal ganglia (TG) obtained at autopsy. Among 970 individual sensory neurons from five subjects, 2.0 to 10.5% were positive for HSV-1 DNA, with a median of 11.3 copies/positive cell, compared with 0.2 to 1.5% of neurons found to be positive by in situ hybridization (ISH) for HSV-1 latency-associated transcripts (LAT), the classical surrogate marker for HSV latency. This indicates a more pervasive latent HSV-1 infection of human TG neurons than originally thought. Combined ISH/LCM/PCR assays revealed that the majority of the latently infected neurons do not accumulate LAT to detectable levels. We detected VZV DNA in 1.0 to 6.9% of individual neurons from 10 subjects. Of the total 1,722 neurons tested, 4.1% were VZV DNA positive, with a median of 6.9 viral genomes/positive cell. After removal by LCM of all visible neurons on a slide, all surrounding nonneuronal cells were harvested and assayed: 21 copies of HSV-1 DNA were detected in approximately 5,200 nonneuronal cells, while nine VZV genomes were detected in approximately 14,200 nonneuronal cells. These data indicate that both HSV-1 and VZV DNAs persist in human TG primarily, if not exclusively, in a moderate percentage of neuronal cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254342      PMCID: PMC1280223          DOI: 10.1128/JVI.79.22.14079-14087.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  Patterns of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses.

Authors:  K D Croen; J M Ostrove; L J Dragovic; S E Straus
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

2.  Ocular herpes simplex virus reactivation in mice latently infected with latency-associated transcript mutants.

Authors:  S D Cook; M J Paveloff; J J Doucet; A J Cottingham; F Sedarati; J M Hill
Journal:  Invest Ophthalmol Vis Sci       Date:  1991-04       Impact factor: 4.799

3.  Detection and characterization of latent HSV RNA by in situ and northern blot hybridization in guinea pigs.

Authors:  R L Burke; K Hartog; K D Croen; J M Ostrove
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

4.  Herpes simplex virus type 1 DNA replication and gene expression during explant-induced reactivation of latently infected murine sensory ganglia.

Authors:  G B Devi-Rao; D C Bloom; J G Stevens; E K Wagner
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

5.  Molecular analysis of herpes simplex virus type 1 during epinephrine-induced reactivation of latently infected rabbits in vivo.

Authors:  D C Bloom; G B Devi-Rao; J M Hill; J G Stevens; E K Wagner
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  In vivo and in vitro reactivation impairment of a herpes simplex virus type 1 latency-associated transcript variant in a rabbit eye model.

Authors:  M D Trousdale; I Steiner; J G Spivack; S L Deshmane; S M Brown; A R MacLean; J H Subak-Sharpe; N W Fraser
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

7.  Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera.

Authors:  R L Ashley; J Militoni; F Lee; A Nahmias; L Corey
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

8.  Two patterns of persistence of herpes simplex virus DNA sequences in the nervous systems of latently infected mice.

Authors:  A Simmons; B Slobedman; P Speck; J Arthur; S Efstathiou
Journal:  J Gen Virol       Date:  1992-05       Impact factor: 3.891

9.  Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site-dependent establishment and reactivation from latency.

Authors:  N M Sawtell; R L Thompson
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Varicella-zoster virus transcription in human trigeminal ganglia.

Authors:  J L Meier; R P Holman; K D Croen; J E Smialek; S E Straus
Journal:  Virology       Date:  1993-03       Impact factor: 3.616

View more
  70 in total

Review 1.  Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Authors:  Robert W Johnson; Marie-José Alvarez-Pasquin; Marc Bijl; Elisabetta Franco; Jacques Gaillat; João G Clara; Marc Labetoulle; Jean-Pierre Michel; Luigi Naldi; Luis S Sanmarti; Thomas Weinke
Journal:  Ther Adv Vaccines       Date:  2015-07

2.  Evidence that the herpes simplex virus type 1 ICP0 protein does not initiate reactivation from latency in vivo.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

3.  The number of herpes simplex virus-infected neurons and the number of viral genome copies per neuron correlate with the latent viral load in ganglia.

Authors:  Yo Hoshino; Jing Qin; Dean Follmann; Jeffrey I Cohen; Stephen E Straus
Journal:  Virology       Date:  2007-11-28       Impact factor: 3.616

4.  Apparent expression of varicella-zoster virus proteins in latency resulting from reactivity of murine and rabbit antibodies with human blood group a determinants in sensory neurons.

Authors:  Leigh Zerboni; Raymond A Sobel; Michelle Lai; Richard Triglia; Megan Steain; Allison Abendroth; Ann Arvin
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

5.  Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.

Authors:  Kening Wang; Georgia D Tomaras; Sinthujan Jegaskanda; M Anthony Moody; Hua-Xin Liao; Kyle N Goodman; Phillip W Berman; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayapan; Jaranit Kaewkungwal; Barton F Haynes; Jeffrey I Cohen
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

6.  Varicella-Zoster Virus (VZV) Small Noncoding RNAs Antisense to the VZV Latency-Encoded Transcript VLT Enhance Viral Replication.

Authors:  Punam Bisht; Biswajit Das; Paul R Kinchington; Ronald S Goldstein
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

7.  Insulin degrading enzyme induces a conformational change in varicella-zoster virus gE, and enhances virus infectivity and stability.

Authors:  Qingxue Li; Mir A Ali; Kening Wang; Dean Sayre; Frederick G Hamel; Elizabeth R Fischer; Robert G Bennett; Jeffrey I Cohen
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

8.  Identification of viral microRNAs expressed in human sacral ganglia latently infected with herpes simplex virus 2.

Authors:  Jennifer L Umbach; Kening Wang; Shuang Tang; Philip R Krause; Erik K Mont; Jeffrey I Cohen; Bryan R Cullen
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

9.  Clinical and molecular aspects of varicella zoster virus infection.

Authors:  Don Gilden; Maria A Nagel; Ravi Mahalingam; Niklaus H Mueller; Elizabeth A Brazeau; Subbiah Pugazhenthi; Randall J Cohrs
Journal:  Future Neurol       Date:  2009-01-01

10.  A historical analysis of herpes simplex virus promoter activation in vivo reveals distinct populations of latently infected neurones.

Authors:  João T Proença; Heather M Coleman; Viv Connor; Douglas J Winton; Stacey Efstathiou
Journal:  J Gen Virol       Date:  2008-12       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.